|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CORO1A |
Gene summary for CORO1A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CORO1A | Gene ID | 11151 |
| Gene name | coronin 1A | |
| Gene Alias | CLABP | |
| Cytomap | 16p11.2 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | A0A024R611 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 11151 | CORO1A | LZE4T | Human | Esophagus | ESCC | 1.10e-14 | 7.34e-01 | 0.0811 |
| 11151 | CORO1A | LZE7T | Human | Esophagus | ESCC | 4.34e-12 | 1.04e+00 | 0.0667 |
| 11151 | CORO1A | LZE8T | Human | Esophagus | ESCC | 9.44e-08 | 6.73e-01 | 0.067 |
| 11151 | CORO1A | LZE22T | Human | Esophagus | ESCC | 1.65e-08 | 4.05e-01 | 0.068 |
| 11151 | CORO1A | LZE24T | Human | Esophagus | ESCC | 1.04e-06 | 2.82e-01 | 0.0596 |
| 11151 | CORO1A | LZE6T | Human | Esophagus | ESCC | 5.13e-27 | 1.84e+00 | 0.0845 |
| 11151 | CORO1A | P2T-E | Human | Esophagus | ESCC | 3.99e-05 | 1.68e-01 | 0.1177 |
| 11151 | CORO1A | P4T-E | Human | Esophagus | ESCC | 5.86e-04 | 1.47e-01 | 0.1323 |
| 11151 | CORO1A | P21T-E | Human | Esophagus | ESCC | 4.36e-03 | 1.29e-01 | 0.1617 |
| 11151 | CORO1A | P28T-E | Human | Esophagus | ESCC | 3.33e-03 | 1.06e-01 | 0.1149 |
| 11151 | CORO1A | P49T-E | Human | Esophagus | ESCC | 4.01e-02 | 3.95e-01 | 0.1768 |
| 11151 | CORO1A | P74T-E | Human | Esophagus | ESCC | 2.40e-08 | 2.94e-01 | 0.1479 |
| 11151 | CORO1A | P75T-E | Human | Esophagus | ESCC | 2.38e-09 | 2.83e-01 | 0.1125 |
| 11151 | CORO1A | P76T-E | Human | Esophagus | ESCC | 3.66e-02 | 9.70e-02 | 0.1207 |
| 11151 | CORO1A | P79T-E | Human | Esophagus | ESCC | 1.05e-03 | 1.56e-01 | 0.1154 |
| 11151 | CORO1A | P83T-E | Human | Esophagus | ESCC | 1.12e-02 | 1.76e-01 | 0.1738 |
| 11151 | CORO1A | P91T-E | Human | Esophagus | ESCC | 8.78e-03 | 2.70e-01 | 0.1828 |
| 11151 | CORO1A | P130T-E | Human | Esophagus | ESCC | 6.55e-08 | 2.63e-01 | 0.1676 |
| 11151 | CORO1A | C04 | Human | Oral cavity | OSCC | 5.38e-05 | 4.11e-01 | 0.2633 |
| 11151 | CORO1A | C21 | Human | Oral cavity | OSCC | 1.83e-23 | 9.88e-01 | 0.2678 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001605014 | Esophagus | ESCC | vesicle organization | 211/8552 | 300/18723 | 2.85e-18 | 2.87e-16 | 211 |
| GO:0043254111 | Esophagus | ESCC | regulation of protein-containing complex assembly | 278/8552 | 428/18723 | 3.81e-16 | 2.77e-14 | 278 |
| GO:0031334111 | Esophagus | ESCC | positive regulation of protein-containing complex assembly | 166/8552 | 237/18723 | 2.06e-14 | 1.07e-12 | 166 |
| GO:001648210 | Esophagus | ESCC | cytosolic transport | 124/8552 | 168/18723 | 9.69e-14 | 4.69e-12 | 124 |
| GO:000703314 | Esophagus | ESCC | vacuole organization | 127/8552 | 180/18723 | 1.04e-11 | 3.85e-10 | 127 |
| GO:1902905111 | Esophagus | ESCC | positive regulation of supramolecular fiber organization | 142/8552 | 209/18723 | 5.51e-11 | 1.76e-09 | 142 |
| GO:1902903111 | Esophagus | ESCC | regulation of supramolecular fiber organization | 237/8552 | 383/18723 | 9.06e-11 | 2.75e-09 | 237 |
| GO:0010639110 | Esophagus | ESCC | negative regulation of organelle organization | 215/8552 | 348/18723 | 8.20e-10 | 2.01e-08 | 215 |
| GO:005149520 | Esophagus | ESCC | positive regulation of cytoskeleton organization | 147/8552 | 226/18723 | 2.93e-09 | 6.38e-08 | 147 |
| GO:003158919 | Esophagus | ESCC | cell-substrate adhesion | 221/8552 | 363/18723 | 3.06e-09 | 6.62e-08 | 221 |
| GO:0051235110 | Esophagus | ESCC | maintenance of location | 200/8552 | 327/18723 | 1.01e-08 | 2.02e-07 | 200 |
| GO:0051258111 | Esophagus | ESCC | protein polymerization | 183/8552 | 297/18723 | 1.94e-08 | 3.75e-07 | 183 |
| GO:000701527 | Esophagus | ESCC | actin filament organization | 259/8552 | 442/18723 | 2.37e-08 | 4.50e-07 | 259 |
| GO:0032273111 | Esophagus | ESCC | positive regulation of protein polymerization | 95/8552 | 138/18723 | 2.97e-08 | 5.57e-07 | 95 |
| GO:0070997111 | Esophagus | ESCC | neuron death | 216/8552 | 361/18723 | 3.49e-08 | 6.45e-07 | 216 |
| GO:003253520 | Esophagus | ESCC | regulation of cellular component size | 227/8552 | 383/18723 | 4.77e-08 | 8.60e-07 | 227 |
| GO:004578527 | Esophagus | ESCC | positive regulation of cell adhesion | 255/8552 | 437/18723 | 5.07e-08 | 9.11e-07 | 255 |
| GO:00989278 | Esophagus | ESCC | vesicle-mediated transport between endosomal compartments | 36/8552 | 43/18723 | 2.90e-07 | 4.20e-06 | 36 |
| GO:0032970111 | Esophagus | ESCC | regulation of actin filament-based process | 231/8552 | 397/18723 | 2.91e-07 | 4.20e-06 | 231 |
| GO:00482844 | Esophagus | ESCC | organelle fusion | 94/8552 | 141/18723 | 3.72e-07 | 5.16e-06 | 94 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0414530 | Esophagus | ESCC | Phagosome | 100/4205 | 152/8465 | 3.81e-05 | 1.72e-04 | 8.82e-05 | 100 |
| hsa051527 | Esophagus | ESCC | Tuberculosis | 111/4205 | 180/8465 | 7.14e-04 | 2.32e-03 | 1.19e-03 | 111 |
| hsa04145114 | Esophagus | ESCC | Phagosome | 100/4205 | 152/8465 | 3.81e-05 | 1.72e-04 | 8.82e-05 | 100 |
| hsa0515212 | Esophagus | ESCC | Tuberculosis | 111/4205 | 180/8465 | 7.14e-04 | 2.32e-03 | 1.19e-03 | 111 |
| hsa051526 | Oral cavity | OSCC | Tuberculosis | 105/3704 | 180/8465 | 5.00e-05 | 2.04e-04 | 1.04e-04 | 105 |
| hsa0414528 | Oral cavity | OSCC | Phagosome | 88/3704 | 152/8465 | 2.83e-04 | 9.13e-04 | 4.65e-04 | 88 |
| hsa0515211 | Oral cavity | OSCC | Tuberculosis | 105/3704 | 180/8465 | 5.00e-05 | 2.04e-04 | 1.04e-04 | 105 |
| hsa04145113 | Oral cavity | OSCC | Phagosome | 88/3704 | 152/8465 | 2.83e-04 | 9.13e-04 | 4.65e-04 | 88 |
| hsa0414529 | Oral cavity | LP | Phagosome | 73/2418 | 152/8465 | 2.37e-07 | 3.29e-06 | 2.12e-06 | 73 |
| hsa0515221 | Oral cavity | LP | Tuberculosis | 65/2418 | 180/8465 | 1.60e-02 | 4.92e-02 | 3.17e-02 | 65 |
| hsa0414536 | Oral cavity | LP | Phagosome | 73/2418 | 152/8465 | 2.37e-07 | 3.29e-06 | 2.12e-06 | 73 |
| hsa0515231 | Oral cavity | LP | Tuberculosis | 65/2418 | 180/8465 | 1.60e-02 | 4.92e-02 | 3.17e-02 | 65 |
| hsa0515241 | Oral cavity | EOLP | Tuberculosis | 47/1218 | 180/8465 | 2.19e-05 | 1.18e-04 | 6.96e-05 | 47 |
| hsa0414543 | Oral cavity | EOLP | Phagosome | 38/1218 | 152/8465 | 3.42e-04 | 1.42e-03 | 8.35e-04 | 38 |
| hsa0515251 | Oral cavity | EOLP | Tuberculosis | 47/1218 | 180/8465 | 2.19e-05 | 1.18e-04 | 6.96e-05 | 47 |
| hsa0414553 | Oral cavity | EOLP | Phagosome | 38/1218 | 152/8465 | 3.42e-04 | 1.42e-03 | 8.35e-04 | 38 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CORO1A | SNV | Missense_Mutation | c.337G>C | p.Asp113His | p.D113H | P31146 | protein_coding | deleterious(0) | benign(0.255) | TCGA-BH-A1FU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| CORO1A | SNV | Missense_Mutation | c.1102G>A | p.Ala368Thr | p.A368T | P31146 | protein_coding | tolerated(0.08) | benign(0.051) | TCGA-C5-A7X5-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | carboplatin | PD | |
| CORO1A | SNV | Missense_Mutation | novel | c.686N>C | p.Val229Ala | p.V229A | P31146 | protein_coding | deleterious(0.02) | benign(0.007) | TCGA-DG-A2KM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| CORO1A | SNV | Missense_Mutation | c.844N>A | p.Val282Ile | p.V282I | P31146 | protein_coding | tolerated(0.45) | benign(0.01) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CORO1A | SNV | Missense_Mutation | c.1102N>A | p.Ala368Thr | p.A368T | P31146 | protein_coding | tolerated(0.08) | benign(0.051) | TCGA-AA-A022-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CORO1A | SNV | Missense_Mutation | rs143294920 | c.373N>A | p.Val125Ile | p.V125I | P31146 | protein_coding | tolerated(0.15) | benign(0.086) | TCGA-AZ-4313-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CORO1A | SNV | Missense_Mutation | c.62C>T | p.Ala21Val | p.A21V | P31146 | protein_coding | deleterious(0.02) | benign(0.099) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| CORO1A | SNV | Missense_Mutation | c.418C>A | p.His140Asn | p.H140N | P31146 | protein_coding | deleterious(0.03) | probably_damaging(0.973) | TCGA-D5-5540-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| CORO1A | SNV | Missense_Mutation | c.549N>G | p.Asp183Glu | p.D183E | P31146 | protein_coding | tolerated(0.05) | benign(0) | TCGA-D5-6530-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| CORO1A | SNV | Missense_Mutation | novel | c.776N>C | p.Leu259Pro | p.L259P | P31146 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-DM-A1D6-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |